The DOI matches its Crossref record; 121 of the 121 references it cites were found in a registry or an index.
Review article: consensus statements on therapeutic drug monitoring of anti‐tumour necrosis factor therapy in inflammatory bowel diseases
Open accessAbstract
Summary: Background: Therapeutic drug monitoring (TDM) in inflammatory bowel disease (IBD) patients receiving anti‐tumour necrosis factor (TNF) agents can help optimise outcomes. Consensus statements based on current evidence will help the development of treatment guidelines. Aim: To develop evidence‐based consensus statements for TDM‐guided anti‐TNF therapy in IBD. Methods: A committee of 25 Australian and international experts was assembled. The initial draft statements were produced following a systematic literature search. A modified Delphi technique was used with 3 iterations. Statements were modified according to anonymous voting and feedback at each iteration. Statements with 80% agreement without or with minor reservation were accepted. Results: 22/24 statements met criteria for consensus. For anti‐TNF agents, TDM should be performed upon treatment failure, following successful induction, when contemplating a drug holiday and periodically in clinical remission only when results would change management. To achieve clinical remission in luminal IBD, infliximab and adalimumab trough concentrations in the range of 3‐8 and 5‐12 μg/mL, respectively, were deemed appropriate. The range may differ for different disease phenotypes or treatment endpoints—such as fistulising disease or to achieve mucosal healing. In treatment failure, TDM may identify mechanisms to guide subsequent decision‐making. In stable clinical response, TDM‐guided dosing may avoid future relapse. Data indicate drug‐tolerant anti‐drug antibody assays do not offer an advantage over drug‐sensitive assays. Further data are required prior to recommending TDM for non‐anti‐TNF biological agents. Conclusion: Consensus statements support the role of TDM in optimising anti‐TNF agents to treat IBD, especially in situations of treatment failure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Delphi Technique: Making Sense of Consensus
Hsu, C.-C., & Sandford, B. A. (2007) · University of Massachusetts Amherst · doi:10.7275/pdz9-th90 · Cited by 4,500 · cited 1×
“for incorporating TDM for anti-TNF agents into modern IBD management.(14-19) Points addressed included scenarios for performing”
MethodQualitative Research: Consensus methods for medical and health services research
Jones, J., & Hunter, D. (1995) · BMJ · doi:10.1136/bmj.311.7001.376 · Cited by 3,471
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
Colombel, J. F., Sandborn, W. J., Reinisch, W., Mantzaris, G. J., Kornbluth, A., Rachmilewitz, D., Lichtiger, S., D'Haens, G., Diamond, R. H., Broussard, D. L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0904492 · Cited by 3,143
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Feagan, B. G., Rutgeerts, P., Sands, B. E., Hanauer, S., Colombel, J.-F., Sandborn, W. J., Van Assche, G., Axler, J., Kim, H.-J., Danese, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215734 · Cited by 2,888
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
Sandborn, W. J., Feagan, B. G., Rutgeerts, P., Hanauer, S., Colombel, J.-F., Sands, B. E., Lukas, M., Fedorak, R. N., Lee, S., Bressler, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215739 · Cited by 2,719
Colombel, J., Sandborn, W. J., Rutgeerts, P., Enns, R., Hanauer, S. B., Panaccione, R., Schreiber, S., Byczkowski, D., Li, J., Kent, J. D., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2006.11.041 · Cited by 2,245
Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
Baert, F., Noman, M., Vermeire, S., Van Assche, G., D' Haens, G., Carbonez, A., & Rutgeerts, P. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020888 · Cited by 2,015
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
Feagan, B. G., Sandborn, W. J., Gasink, C., Jacobstein, D., Lang, Y., Friedman, J. R., Blank, M. A., Johanns, J., Gao, L.-L., Miao, Y., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602773 · Cited by 1,845
Peyrin-Biroulet, L., Sandborn, W., Sands, B. E., Reinisch, W., Bemelman, W., Bryant, R. V., D'Haens, G., Dotan, I., Dubinsky, M., Feagan, B., et al. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.233 · Cited by 1,844
Self-citationEpidemiology and risk factors for IBD
Ananthakrishnan, A. N. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.34 · Cited by 1,741
Sandborn, W. J., van Assche, G., Reinisch, W., Colombel, J., D’Haens, G., Wolf, D. C., Kron, M., Tighe, M. B., Lazar, A., & Thakkar, R. B. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.10.032 · Cited by 1,269
Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
Vande Casteele, N., Ferrante, M., Van Assche, G., Ballet, V., Compernolle, G., Van Steen, K., Simoens, S., Rutgeerts, P., Gils, A., & Vermeire, S. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.02.031 · Cited by 886
Self-citationSandborn, W. J., Feagan, B. G., Marano, C., Zhang, H., Strauss, R., Johanns, J., Adedokun, O. J., Guzzo, C., Colombel, J., Reinisch, W., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.06.010 · Cited by 727
Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management
Roda, G., Jharap, B., Neeraj, N., & Colombel, J.-F. (2016) · Clinical and Translational Gastroenterology · doi:10.1038/ctg.2015.63 · Cited by 723
Ben-Horin, S., & Chowers, Y. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04612.x · Cited by 620
Maser, E. A., Villela, R., Silverberg, M. S., & Greenberg, G. R. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.06.025 · Cited by 613
Halpin, S. J., & Ford, A. C. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.260 · Cited by 607
Efficacy of Biological Therapies in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis
Ford, A. C., Sandborn, W. J., Khan, K. J., Hanauer, S. B., Talley, N. J., & Moayyedi, P. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.73 · Cited by 604
Louis, E., Mary, J., Vernier–Massouille, G., Grimaud, J., Bouhnik, Y., Laharie, D., Dupas, J., Pillant, H., Picon, L., Veyrac, M., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.09.034 · Cited by 597
Schoepfer, A. M., Beglinger, C., Straumann, A., Trummler, M., Vavricka, S. R., Bruegger, L. E., & Seibold, F. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2009.545 · Cited by 570
Seow, C. H., Newman, A., Irwin, S. P., Steinhart, A. H., Silverberg, M. S., & Greenberg, G. R. (2010) · Gut · doi:10.1136/gut.2009.183095 · Cited by 536
Self-citationThe Modified Delphi Technique - A Rotational Modification
Custer, R. L., Scarcella, J. A., & Stewart, B. R. (1999) · Journal of Career and Technical Education · doi:10.21061/jcte.v15i2.702 · Cited by 520
Peyrin-Biroulet, L., Reinisch, W., Colombel, J.-F., Mantzaris, G. J., Kornbluth, A., Diamond, R., Rutgeerts, P., Tang, L. K., Cornillie, F. J., & Sandborn, W. J. (2014) · Gut · doi:10.1136/gutjnl-2013-304984 · Cited by 502
Ordás, I., Mould, D. R., Feagan, B. G., & Sandborn, W. J. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.328 · Cited by 498
Van Assche, G., Magdelaine–Beuzelin, C., D'Haens, G., Baert, F., Noman, M., Vermeire, S., Ternant, D., Watier, H., Paintaud, G., & Rutgeerts, P. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.004 · Cited by 495
Afif, W., Loftus, E. V., Faubion, W. A., Kane, S. V., Bruining, D. H., Hanson, K. A., & Sandborn, W. J. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.9 · Cited by 486
Karmiris, K., Paintaud, G., Noman, M., Magdelaine–Beuzelin, C., Ferrante, M., Degenne, D., Claes, K., Coopman, T., Van Schuerbeek, N., Van Assche, G., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.07.062 · Cited by 478
Steenholdt, C., Brynskov, J., Thomsen, O. Ø., Munck, L. K., Fallingborg, J., Christensen, L. A., Pedersen, G., Kjeldsen, J., Jacobsen, B. A., Oxholm, A. S., et al. (2014) · Gut · doi:10.1136/gutjnl-2013-305279 · Cited by 460
Brandse, J. F., van den Brink, G. R., Wildenberg, M. E., van der Kleij, D., Rispens, T., Jansen, J. M., Mathôt, R. A., Ponsioen, C. Y., Löwenberg, M., & D’Haens, G. R. A. M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.016 · Cited by 433
Menees, S. B., Powell, C., Kurlander, J., Goel, A., & Chey, W. D. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.6 · Cited by 391
Cornillie, F., Hanauer, S. B., Diamond, R. H., Wang, J., Tang, K. L., Xu, Z., Rutgeerts, P., & Vermeire, S. (2014) · Gut · doi:10.1136/gutjnl-2012-304094 · Cited by 374
Ungar, B., Levy, I., Yavne, Y., Yavzori, M., Picard, O., Fudim, E., Loebstein, R., Chowers, Y., Eliakim, R., Kopylov, U., et al. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.10.025 · Cited by 370
Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient
Vande Casteele, N., Gils, A., Singh, S., Ohrmund, L., Hauenstein, S., Rutgeerts, P., & Vermeire, S. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.12 · Cited by 346
Self-citationPredicting the Future: Have you considered using the Delphi Methodology?
Ludwig, B. (1997) · Journal of Extension · doi:10.66752/1077-5315.8000 · Cited by 345
Adedokun, O. J., Sandborn, W. J., Feagan, B. G., Rutgeerts, P., Xu, Z., Marano, C. W., Johanns, J., Zhou, H., Davis, H. M., Cornillie, F., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.08.035 · Cited by 341
Nanda, K. S., Cheifetz, A. S., & Moss, A. C. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.363 · Cited by 336
Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis
Fasanmade, A. A., Adedokun, O. J., Ford, J., Hernandez, D., Johanns, J., Hu, C., Davis, H. M., & Zhou, H. (2009) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-009-0718-4 · Cited by 327
THE DELPHI TECHNIQUE: MAKING SENSE OF CONSENSUS PRACTICAL ASSESSMENT
Hsu, C.-T., & Sandford, B. A. (2007) · Cited by 318
Yanai, H., Lichtenstein, L., Assa, A., Mazor, Y., Weiss, B., Levine, A., Ron, Y., Kopylov, U., Bujanover, Y., Rosenbach, Y., et al. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.07.029 · Cited by 316
Ben–Horin, S., Waterman, M., Kopylov, U., Yavzori, M., Picard, O., Fudim, E., Awadie, H., Weiss, B., & Chowers, Y. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.10.020 · Cited by 310
Ding, N. S., Hart, A., & De Cruz, P. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13445 · Cited by 309
Ungar, B., Chowers, Y., Yavzori, M., Picard, O., Fudim, E., Har-Noy, O., Kopylov, U., Eliakim, R., Ben-Horin, S., & on behalf of ABIRISK consortium (2014) · Gut · doi:10.1136/gutjnl-2013-305259 · Cited by 309
Yarur, A. J., Kanagala, V., Stein, D. J., Czul, F., Quintero, M. A., Agrawal, D., Patel, A., Best, K., Fox, C., Idstein, K., et al. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13970 · Cited by 308
Dotan, I., Ron, Y., Yanai, H., Becker, S., Fishman, S., Yahav, L., Ben Yehoyada, M., & Mould, D. R. (2014) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000212 · Cited by 291
Vande Casteele, N., Khanna, R., Levesque, B. G., Stitt, L., Zou, G. Y., Singh, S., Lockton, S., Hauenstein, S., Ohrmund, L., Greenberg, G. R., et al. (2015) · Gut · doi:10.1136/gutjnl-2014-307883 · Cited by 289
Self-citationChang, J., Leong, R. W., Wasinger, V. C., Ip, M., Yang, M., & Phan, T. G. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.05.056 · Cited by 286
Self-citationRoblin, X., Marotte, H., Rinaudo, M., Del Tedesco, E., Moreau, A., Phelip, J. M., Genin, C., Peyrin–Biroulet, L., & Paul, S. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.07.010 · Cited by 279
Clinical Pharmacokinetics and Use??of??Infliximab
Klotz, U., Teml, A., & Schwab, M. (2007) · Clinical Pharmacokinetics · doi:10.2165/00003088-200746080-00002 · Cited by 261
Keohane, J., O'Mahony, C., O'Mahony, L., O'Mahony, S., Quigley, E. M., & Shanahan, F. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.156 · Cited by 253
Papamichael, K., Gils, A., Rutgeerts, P., Levesque, B. G., Vermeire, S., Sandborn, W. J., & Casteele, N. V. (2015) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000202 · Cited by 243
Yarur, A. J., Jain, A., Sussman, D. A., Barkin, J. S., Quintero, M. A., Princen, F., Kirkland, R., Deshpande, A. R., Singh, S., & Abreu, M. T. (2016) · Gut · doi:10.1136/gutjnl-2014-308099 · Cited by 242
Bortlik, M., Duricova, D., Malickova, K., Machkova, N., Bouzkova, E., Hrdlicka, L., Komarek, A., & Lukas, M. (2013) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2012.10.019 · Cited by 232
Louis, E., El Ghoul, Z., Vermeire, S., Dall'Ozzo, S., Rutgeerts, P., Paintaud, G., Belaiche, J., De Vos, M., Van Gossum, A., Colombel, J. ‐., et al. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.01871.x · Cited by 224
Current best practice for disease activity assessment in IBD
Walsh, A. J., Bryant, R. V., & Travis, S. P. L. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.128 · Cited by 223
Self-citationPaul, S., Del Tedesco, E., Marotte, H., Rinaudo-Gaujous, M., Moreau, A., Phelip, J.-M., Genin, C., Peyrin-Biroulet, L., & Roblin, X. (2013) · Inflammatory Bowel Diseases · doi:10.1097/mib.0b013e3182a77b41 · Cited by 222
Key findings towards optimising adalimumab treatment: the concentration–effect curve
Pouw, M. F., Krieckaert, C. L., Nurmohamed, M. T., van der Kleij, D., Aarden, L., Rispens, T., & Wolbink, G. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204172 · Cited by 214
Wang, S.-L., Ohrmund, L., Hauenstein, S., Salbato, J., Reddy, R., Monk, P., Lockton, S., Ling, N., & Singh, S. (2012) · Journal of Immunological Methods · doi:10.1016/j.jim.2012.06.002 · Cited by 208
Gisbert, J. P., Marín, A. C., & Chaparro, M. (2016) · American Journal of Gastroenterology · doi:10.1038/ajg.2016.54 · Cited by 204
Notley, C. A., Inglis, J. J., Alzabin, S., McCann, F. E., McNamee, K. E., & Williams, R. O. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20072707 · Cited by 196
Roblin, X., Rinaudo, M., Del Tedesco, E., Phelip, J. M., Genin, C., Peyrin-Biroulet, L., & Paul, S. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.146 · Cited by 195
Paradoxical inflammation induced by anti-TNF agents in patients with IBD
Cleynen, I., & Vermeire, S. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.125 · Cited by 193
Svenson, M., Geborek, P., Saxne, T., & Bendtzen, K. (2007) · Rheumatology · doi:10.1093/rheumatology/kem261 · Cited by 189
Mazor, Y., Almog, R., Kopylov, U., Ben Hur, D., Blatt, A., Dahan, A., Waterman, M., Ben‐Horin, S., & Chowers, Y. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12869 · Cited by 189
Infliximab Pharmacokinetics in Inflammatory Bowel Disease Patients
Ternant, D., Aubourg, A., Magdelaine-Beuzelin, C., Degenne, D., Watier, H., Picon, L., & Paintaud, G. (2008) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e318180e300 · Cited by 188
van der Laken, C. J., Voskuyl, A. E., Roos, J. C., Stigter van Walsum, M., de Groot, E. R., Wolbink, G., Dijkmans, B. A. C., & Aarden, L. A. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.057406 · Cited by 184
Steenholdt, C., Bendtzen, K., Brynskov, J., Thomsen, O. Ø., & Ainsworth, M. A. (2011) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2010.536254 · Cited by 175
Delphi Technique: Expanding Applications.
Brooks, K. W. (1979) · The North Central Association quarterly · Cited by 166
Papamichael, K., Van Stappen, T., Vande Casteele, N., Gils, A., Billiet, T., Tops, S., Claes, K., Van Assche, G., Rutgeerts, P., Vermeire, S., et al. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.11.014 · Cited by 161
Self-citationSingh, N., Rosenthal, C. J., MELMED, G. Y., Mirocha, J., Farrior, S., Callejas, S., Tripuraneni, B., Rabizadeh, S., & Dubinsky, M. C. (2014) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000137 · Cited by 155
Pierik, M. J., Vermeire, S., Steen, K. V., Joossens, S. B. A., Claessens, G., VLIETINCK, R. F., & Rutgeerts, P. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.01946.x · Cited by 151
Takeuchi, T., Miyasaka, N., Tatsuki, Y., Yano, T., Yoshinari, T., Abe, T., & Koike, T. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2011.153023 · Cited by 151
Sprakes, M. B., Ford, A. C., Warren, L. R., Greer, D., & Hamlin, P. J. (2011) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2011.07.011 · Cited by 149
Steenholdt, C., Bendtzen, K., Brynskov, J., Thomsen, O. Ø., & Ainsworth, M. A. (2014) · The American Journal of Gastroenterology · doi:10.1038/ajg.2014.106 · Cited by 136
Rojas, J. R., Taylor, R. P., Cunningham, M. R., Rutkoski, T. J., Vennarini, J., Jang, H., Graham, M. A., Geboes, K. J., Rousselle, S. D., & Wagner, C. L. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.079277 · Cited by 130
Colombel, J., Sandborn, W. J., Allez, M., et al. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.10.025 · Cited by 129
The Delphi Technique: A Case Study.
Cyphert, F. R., & Gant, W. L. (1971) · Phi Delta Kappan · Cited by 122
Ungar, B., Kopylov, U., Engel, T., Yavzori, M., Fudim, E., Picard, O., Lang, A., Williet, N., Paul, S., Chowers, Y., et al. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13862 · Cited by 118
Steenholdt, C., Ainsworth, M. A., Tovey, M. G., Klausen, T. W., Thomsen, O. Ø., Brynskov, J., & Bendtzen, K. (2013) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e31828d23c3 · Cited by 116
Yarur, A. J., Jain, A., Hauenstein, S. I., Quintero, M. A., Barkin, J. S., Deshpande, A. R., Sussman, D. A., Singh, S., & Abreu, M. T. (2016) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000689 · Cited by 114
Stappen, T. V., Casteele, N. V., Assche, G. V., Ferrante, M., Vermeire, S., & Gils, A. (2017) · Gut · doi:10.1136/gutjnl-2016-313071 · Cited by 109
Steenholdt, C., Al-Khalaf, M. A. R., Brynskov, J., Bendtzen, K., Thomsen, O., & Ainsworth, M. A. (2012) · Inflammatory Bowel Diseases · doi:10.1002/ibd.22910 · Cited by 106
Sharma, S., Eckert, D., Hyams, J. S., Mensing, S., Thakkar, R. B., Robinson, A. M., Rosh, J. R., Ruemmele, F. M., & Awni, W. M. (2015) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000327 · Cited by 105
Developing a Therapeutic Range of Adalimumab Serum Concentrations in Management of Psoriasis
Menting, S. P., Coussens, E., Pouw, M. F., et al. (2015) · JAMA Dermatology · doi:10.1001/jamadermatol.2014.5479 · Cited by 104
Casteele, N. V., & Gils, A. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.374 · Cited by 101
Levesque, B. G., Greenberg, G. R., Zou, G., Sandborn, W. J., Singh, S., Hauenstein, S. I., Ohrmund, L., Wong, C. J., Stitt, L., Shackelton, L. M., et al. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12733 · Cited by 101
Berrill, J., Green, J. T., Hood, K., & Campbell, A. K. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12335 · Cited by 101
Pharmacokinetics and concentration–effect relationship of adalimumab in rheumatoid arthritis
Ternant, D., Ducourau, É., Fuzibet, P., Desvignes, C., Watier, H., Lequerré, T., Loët, X. L., Vittecoq, O., Goupille, P., Mulleman, D., et al. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12509 · Cited by 100
Lallemand, C., Kavrochorianou, N., Steenholdt, C., Bendtzen, K., Ainsworth, M. A., Méritet, J., Blanchard, B., Lebon, P., Taylor, P. C., Charles, P. J., et al. (2011) · Journal of Immunological Methods · doi:10.1016/j.jim.2011.08.022 · Cited by 99
Pharmacokinetics of Adalimumab in Inflammatory Bowel Diseases
Paul, S., Carla-Moreau, A., Tedesco, É. D., Rinaudo, M., Phelip, J., Genin, C., Peyrin‐Biroulet, L., & Roblin, X. (2014) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000037 · Cited by 99
Steenholdt, C., Bendtzen, K., Brynskov, J., & Ainsworth, M. A. (2016) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000772 · Cited by 98
Baert, F., Kondragunta, V., Lockton, S., Casteele, N. V., Hauenstein, S. I., Singh, S., Κarmiris, K., Ferrante, M., Gils, A., & Vermeire, S. (2015) · Gut · doi:10.1136/gutjnl-2014-307882 · Cited by 94
Louis, E. J., Watier, H., Schreiber, S., Hampe, J., Taillard, F., Olson, A. D., Thorne, N., Zhang, H., & Colombel, J. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000230421.12844.fd · Cited by 92
Ungar, B., Mazor, Y., Weisshof, R., Yanai, H. A., Ron, Y., Goren, I., Waizbard, A., Yavzori, M., Fudim, E., Picard, O., et al. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13631 · Cited by 91
Lee, H., Park, S. H., Kim, S., Kim, J., Choi, J., Lee, H. J., Kim, W. S., Lee, J.-M., Kwak, M. S., Hwang, S. W., et al. (2016) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000675 · Cited by 90
Quigley, E. M. M. (2015) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x15621230 · Cited by 89
Review article: acute severe ulcerative colitis – evidence‐based consensus statements
Chen, J., Andrews, J. M., Kariyawasam, V. C., Moran, N., Gounder, P., Collins, P. G. S., Walsh, A. J., Connor, S. J., Lee, T. W. T., Koh, C., et al. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13670 · Cited by 82
Self-citationCharacterization of IBS ‐like symptoms in patients with ulcerative colitis in clinical remission
Jonefjäll, B., Strid, H., Öhman, L., Svedlund, J., Bergstedt, A., & Simrén, M. (2013) · Neurogastroenterology & Motility · doi:10.1111/nmo.12163 · Cited by 77
Barratt, S. M., Leeds, J. S., Robinson, K., Shah, P. J., Lobo, A., McAlindon, M. E., & Sanders, D. S. (2010) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e328342a547 · Cited by 77
Review: Predicting response to anti-TNF agents for the treatment of Crohn's disease
Siegel, C. A., & MELMED, G. Y. (2009) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x09336364 · Cited by 76
Buurman, D. J., Maurer, J. M., Keizer, R. J., Kosterink, J. G. W., & Dijkstra, G. D. H. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13299 · Cited by 75
Biologic Concentration Testing in Inflammatory Bowel Disease
Vaughn, B. P., Sandborn, W. J., & Cheifetz, A. S. (2015) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000312 · Cited by 73
Yarur, A. J., & Rubin, D. T. (2015) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000380 · Cited by 66
Optimization of anti-TNF therapy in patients with Inflammatory Bowel Disease
Strik, A. S., Bots, S. J., D’Haens, G., & Löwenberg, M. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1133288 · Cited by 56
Yamada, A., Sono, K., Hosoe, N., Takada, N., & Suzuki, Y. (2010) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21259 · Cited by 53
Therapeutic drug monitoring of infliximab: performance evaluation of three commercial ELISA kits
Schmitz, E. M. H., van de Kerkhof, D., Hamann, D., van Dongen, J. L. J., Kuijper, P. H. M., Brunsveld, L., Scharnhorst, V., & Broeren, M. A. C. (2015) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2015-0987 · Cited by 53
Jelsness‐Jørgensen, L., Bernklev, T., & Moum, B. A. (2013) · Gastroenterology Research and Practice · doi:10.1155/2013/620707 · Cited by 51
Practical Use of Infliximab Concentration Monitoring in Pediatric Crohn Disease
Minar, P., Saeed, S. A., Afreen, M., Kim, M., & Denson, L. A. (2015) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000001029 · Cited by 51
Chowers, Y., Sturm, A., Sans, M., Papadakis, K. A., Gazouli, M., Harbord, M., Jahnel, J., Mantzaris, G. J., Meier, J., Mottet, C., et al. (2010) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2010.05.011 · Cited by 48
Casteele, N. V., Compernolle, G., Ballet, V., Assche, G. V., Gils, A., Vermeire, S., & Rutgeerts, P. J. (2012) · Gastroenterology · doi:10.1016/s0016-5085(12)60792-6 · Cited by 42
What to Do When Biologic Agents Are Not Working in Inflammatory Bowel Disease Patients.
Dalal, S. R., & Cohen, R. D. (2015) · PubMed Central · Cited by 39
Barratt, S. M., Leeds, J. S., Robinson, K., Lobo, A. J., McAlindon, M. E., & Sanders, D. S. (2011) · Digestive Diseases and Sciences · doi:10.1007/s10620-011-1783-y · Cited by 37
Jelsness‐Jørgensen, L., Bernklev, T., & Moum, B. A. (2012) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2012.08.009 · Cited by 35
TNF Blocking Therapies and Immunomonitoring in Patients with Inflammatory Bowel Disease
Altwegg, R., & Vincent, T. (2014) · Mediators of Inflammation · doi:10.1155/2014/172821 · Cited by 31
Therapeutic drug monitoring of anti-tumour necrosis factor-α agents in inflammatory bowel disease
Mitrev, N., & Leong, R. W. L. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1269169 · Cited by 31
Self-citationAssays for Infliximab Drug Levels and Antibodies: A Matter of Scales and Categories
Bader, L., Solberg, S. M., Kaada, S. H., Bolstad, N., Warren, D. J., Gavasso, S., Gjesdal, C. G., & Vedeler, C. A. (2017) · Scandinavian Journal of Immunology · doi:10.1111/sji.12572 · Cited by 28
Steenholdt, C., Frederiksen, M. T., Bendtzen, K., Ainsworth, M. A., Thomsen, O. Ø., & Brynskov, J. (2015) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000375 · Cited by 22
Optimizing Biologic Agents in Ulcerative Colitis and Crohn’s Disease
O’Toole, A., & Moss, A. C. (2015) · Current Gastroenterology Reports · doi:10.1007/s11894-015-0453-1 · Cited by 21
Guiotto, C., Daperno, M., Frigerio, F., Vizzini, M., Cerruti, R., Ercole, E., Cosimato, M., Lavagna, A., Germano, L., Migliardi, M., et al. (2015) · Digestive and Liver Disease · doi:10.1016/j.dld.2015.10.023 · Cited by 19
Steenholdt, C., Brynskov, J., Thomsen, O. Ø., Munck, L. K., Christensen, L. A., Pedersen, G., Kjeldsen, J., & Ainsworth, M. A. (2015) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjv139 · Cited by 18
Hlavatý, T., Krajčovičová, A., Letkovský, J., et al. (2016) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.4149/bll_2016_039 · Cited by 13
Ungar, B., Yavzori, M., Fudim, E., Picard, O., Kopylov, U., Tedesco, É. D., Paul, S., Chowers, Y., Eliakim, A. R., Ben‐Horin, S., et al. (2016) · Gastroenterology · doi:10.1016/s0016-5085(16)31441-x · Cited by 2
Metadata
- Authors
- Mitrev, N., Vande Casteele, N., Seow, C. H., Andrews, J. M., Connor, S. J., Moore, G. T., Barclay, M., Begun, J., Bryant, R., Chan, W., Corte, C., Ghaly, S., Lemberg, D. A., Kariyawasam, V., Lewindon, P., Martin, J., Mountifield, R., Radford‐Smith, G., Slobodian, P., Sparrow, M., Toong, C., van Langenberg, D., Ward, M. G., Leong, R. W., & IBD Sydney Organisation and the Australian Inflammatory Bowel Diseases Consensus Working Group
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2017-10-13
- Volume
- 46
- Issue
- 11-12
- Pages
- 1037-1053
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W2764071025
- Cited by
- 282
- References
- 121
- FWCI
- 21.77
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
